Azenta (AZTA) Q3 2026 Earnings Call Transcript
Azenta (AZTA) held its Q3 2026 earnings call. CEO John Marotta said revenue exceeded outlook, profitability improved sequentially, and Multiomics grew year over year, with organic revenue up 9% YoY. The company revised FY2026 guidance to reported revenue of $613M to $618M and adjusted EBITDA of $59M to $62M, citing uneven demand and turnaround progress.
How this was made
The 30-second read
Why it matters
Traders can use the explicit FY2026 revenue and adjusted EBITDA ranges, plus qualitative execution milestones (AI-enabled biorepository deployment, automated store remediation completion in testing, UKBC integration progress) to update models and near-term expectations.
Market read
Fresh FY2026 guidance ranges and turnaround execution updates are likely to drive estimate changes and near-term positioning in lab automation and sample management names.
What to watch
The excerpt notes remediation spending largely behind them but acceptance is not fully complete until remaining systems pass customer sign-off, which could delay revenue recognition and margin improvement.
Background
Azenta’s management discusses Q3 progress on its Multiomics and Sample Management Solutions turnaround, including recurring revenue growth and automated store remediation status.
Ticker impact
Azenta guides FY2026 revenue to $613M-$618M and adjusted EBITDA to $59M-$62M after Q3 revenue beat and ongoing Multiomics turnaround actions.
Moderate volatility around the earnings call as traders reprice the FY2026 revenue and adjusted EBITDA ranges and the credibility of the Multiomics and automated stores turnaround.
This is a primary earnings call transcript with explicit guidance ranges and specific execution milestones, but the excerpt ends before full Q&A and does not include consensus comparisons or margin drivers beyond the ranges.
Market effects
Signals ongoing demand caution in life-science tools while highlighting traction in recurring revenue and automated storage solutions.
North America remains the key swing factor with improved funding visibility but research spending still below prior year levels.
Europe and China show relative strength, supporting a more regionally balanced read-through for lab automation and sample management demand.
Counterpoint
The guidance implies limited organic growth (flat to up 1%), so the market may focus more on execution risk in automated stores and Multiomics recovery than on the Q3 beat.
Key entities
- companyAzenta
Subject of the earnings call transcript, providing Q3 performance commentary and revised FY2026 guidance.
- executiveJohn Marotta
CEO who outlines turnaround progress and Q4 priorities.
- executiveLawrence Lin
CFO who reviews financial results and outlook for fiscal year 2026.
